Altrip 6.25 mg (Tablet)

Indications

• Treatment of acute headache phase of migraine attacks
• Treating migraine with or without aura in adolescents aged 12 to 17 years

Pharmacology

• Selective and potent serotonin (5-hydroxytryptamine 1B/1D) agonist
• Binds to specific serotonin receptors on meningeal arteries
• Inhibits release of vasoactive peptides
• Causes constriction of the arteries
• Limited effect on arteries supplying blood to the brain
• Little effect on cardiac and pulmonary vessels

Dosage & Administration

• Recommended dose in adults and adolescents: 6.25 mg to 12.5 mg
• 12.5 mg dose tends to be more effective in adults
• Maximum daily dose not to exceed 25 mg
• Recommended starting dose in hepatic impairment patients: 6.25 mg
• Maximum daily dose in hepatic impairment: 12.5 mg
• Recommended starting dose in severe renal impairment patients: 6.25 mg
• Maximum daily dose in severe renal impairment: 12.5 mg

Interaction

• May cause prolonged vasospastic reactions
• Risk of serotonin syndrome with SSRIs or SNRIs

Contraindications

• Not to be used in patients with history, symptoms, or signs of ischaemic heart disease
• Contraindicated with ergotamine, ergotamine derivatives, and other 5-HT1B/1D agonists

Side Effects

• Serious cardiac reactions reported, including myocardial infarction

Pregnancy & Lactation

• Pregnancy Category C
• No data on excretion of almotriptan in human milk

Precautions & Warnings

• Hypersensitivity to the active substance or excipients
• Severe hepatic impairment
• Previous cerebrovascular accident (CVA) or transient ischaemic attack (TIA)
• Peripheral vascular disease

Therapeutic Class

• 5-HT Agonists

Storage Conditions

• Keep below 30°C
• Keep in a dry place
• Protected from light
• Do not freeze
• Keep out of the reach of children

Related Brands